Commercial vial demand for SYFOVRE grew by 7% quarter ... The FDA approval and launch of CASGEVY, a gene therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia ...

The FDA approval and launch of CASGEVY, a gene therapy for treating ... reaching key milestones such as generating continued growth in vial demand for SYFOVRE. Commercial vial demand for SYFOVRE ...

Casgevy, a gene therapy for sickle cell disease and beta thalassemia developed with Vertex Pharmaceuticals, has had a fairly slow rollout, but its launch seems to be gaining momentum. Fifty ...

While there is plenty of excitement about the new gene editing treatment, Casgevy, some in the sickle-cell community say they have been let down before and worry about being let down again.

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

CRISPR Therapeutics did not record any collaboration expense for the fourth quarter of 2024, as it had reached the cost deferral limit for the Casgevy program in the previous quarter. As of Dec ...

In the year-ago period, CRISPR Therapeutics received a major milestone payment from partner Vertex Pharmaceuticals VRTX in connection with the approval of one-shot gene therapy Casgevy for two ...

Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes.

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...